TARPEYO Reduces the Loss of Kidney Function in IgA Nephropathy
Автор: DocWire
Загружено: 2024-01-12
Просмотров: 2862
The US Food and Drug Administration (FDA) Recently announced full approval of TARPEYO® (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary IgA nephropathy (IgAN). TARPEYO’s full FDA approval is a significant milestone for the IgAN community.
The full approval is based on the 2-year results of the global phase 3 NefIgArd study, the first and only Phase 3 IgAN trial to show confirmed, statistically significant benefit over placebo in eGFR sustained over a 2-year period.
Nephrology Times spoke with Richard Lafayette, MD, FACP, the primary investigator of the NefIgArd trial, about the study, and the clinical impact of TARPEYO on the nephrology community.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
